IL37 and melanoma: However, IL-23 reduces both cytotoxicity and IFN-γ production in vivo, indeed anti-IL-23 therapy synergizes with IL-2 or anti-erbB2 treatment in mammary and melanoma tumor models in an NK cell-dependent manner (55, 92).